Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Benjamin J. Huang, MD, Xinyue Wang, BA, Max Harris, BA, Anica Wandler, PhD, Eugene Hwang, BA, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Paul Severson, PhD, Ben Powell, PhD, Edward A. Kolb, MD, Soheil Meshinchi, MDPhD, Barry S Taylor, PhD, Gideon Bollag, PhD, Kevin M. Shannon, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142921

Published: 2020

Journal Articles

Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia

Lauren K. Meyer, Benjamin Huang, MD, Ritu Roy, PhD, Aaron Hechmer, PhD, Anica Wandler, PhD, Cristina Delgado-Martin, PhD, Adam B. Olshen, PhD, Terzah M. Horton, MD PhD, David T Teachey, MD, Kevin M. Shannon, MD, Michelle L. Hermiston, MD PhD

Blood (2018) 132 (Supplement 1): 913.

https://doi.org/10.1182/blood-2018-99-119930

Published: 2018

Journal Articles

Genetic Validation of the Palmitoylation/Depalmitoylation Cycle As a Drug Target in NRAS Mutant Hematologic Malignancies In Vivo

Noemi A. Zambetti, PhD, Ari J. Firestone, PhD, Jasmine C. Wong, PhD, Amanda Long, BA, Anagha Inguva, BA, Radu M. Suciu, B.Sc., Benjamin F. Cravatt, PhD, Kevin M. Haigis, PhD, Kevin M. Shannon, MD

Blood (2017) 130 (Supplement 1): 1221.

https://doi.org/10.1182/blood.V130.Suppl_1.1221.1221

Published: 2017

Journal Articles

The PI3K Inhibitor GDC-0941 Attenuates Disease in a Kras G12D Mouse Model of CMML and JMML.

Jon Akutagawa, B.S., Monique Dail, PhD, Lori S Friedman, PhD, Kevin M. Shannon, MD, Deepak Sampath, PhD, Benjamin S. Braun, MD, PhD

Blood (2012) 120 (21): 2862.

https://doi.org/10.1182/blood.V120.21.2862.2862

Published: 2012

Journal Articles

Oncogenic Nras Increases Hematopoietic Stem Cell Proliferation and Self-Renewal Through a Bimodal Effect

Qing Li, M.D., Ph.D., Natacha Bohin, B.S., Tiffany Wen, B.S., Kevin M. Shannon, MD, Sean J. Morrison, Ph.D

Blood (2012) 120 (21): 119.

https://doi.org/10.1182/blood.V120.21.119.119

Published: 2012

Journal Articles

Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9 -Specified Gene Expression Signature

Zohar Sachs, MD, PhD, Hanh Nguyen, Nurul Azyan Mohd Hassan, Susan K Rathe, Karen Sachs, Ph. D., Ernesto Diaz-Flores, PhD, Sean C Bendall, PhD, Miechaleen D Diers, Garry P. Nolan, Ph. D., Kevin M. Shannon, MD, David A. Largaespada, PhD

Blood (2012) 120 (21): 5116.

https://doi.org/10.1182/blood.V120.21.5116.5116

Published: 2012

Journal Articles

MEK Inhibition Modulates the Growth of Nf1 mutant Hematopoietic Cells and Induces Clinical Improvement in a Murine Model of Juvenile Myelomonocytic Leukemia (JMML)

Tiffany Y. Chang, MD, Kimberly Krisman, BA, Emily Rose Harding-Theobald, BA, Benjamin S. Braun, MD, PhD, Kevin M. Shannon, MD

Blood (2011) 118 (21): 797.

https://doi.org/10.1182/blood.V118.21.797.797

Published: 2011

Journal Articles

Mechanisms of Relapse Following Targeted Therapy in An NRAS G12V and Mll-AF9 Driven Mouse Model of AML

Craig E. Eckfeldt, MD, PhD, Ernesto Diaz-Flores, PhD, Michaeleen D. Diers, Susan K. Rathe, Kevin M. Shannon, MD, David A. Largaespada, PhD

Blood (2011) 118 (21): 2620.

https://doi.org/10.1182/blood.V118.21.2620.2620

Published: 2011

Journal Articles

Heterozygous Germ Line Deletion of a 2Mb Interval in Mice That Models Loss of 7q22 in Human Myeloid Malignancies Results in Defective Hematopoietic Stem Cell Function Reminiscent of Premature Aging

Jasmine C. Wong, PhD, Kelley Weinfurtner, BA, Yan Zhang, Ph.D., Pilar Alzamora, Eugene Hwang, BA, Scott C. Kogan, MD, Kevin M. Shannon, MD

Blood (2011) 118 (21): 2340.

https://doi.org/10.1182/blood.V118.21.2340.2340

Published: 2011

Journal Articles

Delineating Critical Effectors of Remission Induction in a Mouse Model of AML

Zohar Sachs, MD, PhD, Susan K. Rathe, Ernesto Diaz-Flores, PhD, Miechaleen D Diers, Kevin M. Shannon, MD, David A. Largaespada, PhD

Blood (2011) 118 (21): 5232.

https://doi.org/10.1182/blood.V118.21.5232.5232

Published: 2011

Journal Articles

Bcl11a Causes p21 Cip1 Down-Regulation and Transplantable Leukemia in Nf1 -Deficient Mice.

Bin Yin, PhD, Ruud Delwel, PhD, Peter J. Valk, PhD, Mignon L. Loh, MD, Kevin M. Shannon, MD, David A. Largaespada, PhD

Blood (2007) 110 (11): 2657.

https://doi.org/10.1182/blood.V110.11.2657.2657

Published: 2007

Journal Articles

Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition.

Jennifer O. Lauchle, MD, Doan T. Le, MD, Doris Kim, Keiko Akagi, PhD, Matthew F. Gorman, MD, Mary Tran, Judith Sebolt-Leopold, PhD, Linda Wolff, PhD, Luis F. Parada, PhD, Nancy Jenkins, PhD, Neal Copeland, PhD, Kevin M. Shannon, MD

Blood (2007) 110 (11): 594.

https://doi.org/10.1182/blood.V110.11.594.594

Published: 2007

Journal Articles

A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days.

Nikesh Kotecha, Nikki J. Flores, Jonathan M. Irish, PhD, Debbie Sakaguchi, MD, Sophie Archambeault, Ernesto Diaz-Flores, PhD, Marc Coram, PhD, Kevin M. Shannon, MD, Garry P. Nolan, PhD, Mignon L. Loh, MD

Blood (2007) 110 (11): 546.

https://doi.org/10.1182/blood.V110.11.546.546

Published: 2007

Journal Articles

Bcl11a Causes Leukemia/Lymphoma in Cooperation with Nf1 Inactivation.

Bin Yin, PhD, Jennifer L. Jeske-Geurts, Miechaleen D. Diers, Kevin M. Shannon, MD, David A. Largaespada, PhD

Blood (2006) 108 (11): 387.

https://doi.org/10.1182/blood.V108.11.387.387

Published: 2006

Journal Articles

RAS and G-CSF Receptor Mutations Are Mutually Exclusive in Leukemogenesis in Severe Congenital Neutropenia.

Manuela Germeshausen, PhD, Chris Kratz, MD, Matthias Ballmaier, PhD, Kevin M. Shannon, MD, Karl Welte, MD

Blood (2005) 106 (11): 3073.

https://doi.org/10.1182/blood.V106.11.3073.3073

Published: 2005

Journal Articles

Oncogenic Ras Requires SHP-2 To Induce Myeloproliferative Disease (MPD).

Benjamin S. Braun, MD, PhD, Joehleen Archard, Wentian Yang, PhD, Gordon Chan, PhD, Benjamin G. Neel, MD, PhD, Kevin M. Shannon, MD

Blood (2005) 106 (11): 3517.

https://doi.org/10.1182/blood.V106.11.3517.3517

Published: 2005

Journal Articles

Multiparameter Flow Cytometric Analysis Reveals Aberrant Phosphorylation of a Network of Effector Molecules in Defined Populations of Kras Mutant Bone Marrow.

Margaret E.M. Van Meter, BA, Ernesto Diaz-Flores, PhD, Joehleen A. Archard, BS, Nikesh Kotecha, BS, Amit J. Sabnis, BS, Jonathan M. Irish, PhD, Garry P. Nolan, PhD, Kevin M. Shannon, MD, Benjamin S. Braun, MD, PhD

Blood (2005) 106 (11): 239.

https://doi.org/10.1182/blood.V106.11.239.239

Published: 2005

Journal Articles

Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML).

Jennifer O. Lauchle, MD, Doan Le, MD, Doris Kim, BA, Mary Tran, BA, Abigail Peterson, BA, Sally Przybranowski, PhD, Luis Parada, PhD, Linda Wolff, PhD, Judith Leopold, PhD, Kevin M. Shannon, MD

Blood (2005) 106 (11): 496.

https://doi.org/10.1182/blood.V106.11.496.496

Published: 2005

Journal Articles

Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.

Suzanne Schubbert, Martin Zenker, MD, Sara L. Rowe, Silke Böll, Cornelia Klein, Ineke van der Burgt, MD, Luciana Musante, PhD, Hoa Nguyen, Brian West, PhD, Gideon Bollag, PhD, Charlotte M. Niemeyer, MD, Kevin M. Shannon, MD, Christian P. Kratz, MD

Blood (2005) 106 (11): 1602.

https://doi.org/10.1182/blood.V106.11.1602.1602

Published: 2005

Journal Articles

Outcomes in CCG-2961, a Children’s Cancer Group Phase III Trial for Untreated Acute Myeloid Leukemia (AML).

Beverly J. Lange, MD, Franklin O. Smith, MD, Patricia A. Dinndorf, MD, Carola A.S. Arndt, MD, Dorothy R. Barnard, MD, Kathryn Dusenbery, MD, Steven A. Feig, MD, James H. Feusner, MD, Sandra Luna-Fineman, MD, Joseph Neglia, MD, MPH, Nita L. Seibel, MD, Leonard Sender, MD, Kevin M. Shannon, MD, Margie Weiman, RN, Robert B. Gerbing, MA, Todd A. Alonzo, PhD

Blood (2005) 106 (11): 169.

https://doi.org/10.1182/blood.V106.11.169.169

Published: 2005

NARROW

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia

Genetic Validation of the Palmitoylation/Depalmitoylation Cycle As a Drug Target in NRAS Mutant Hematologic Malignancies In Vivo

The PI3K Inhibitor GDC-0941 Attenuates Disease in a Kras G12D Mouse Model of CMML and JMML.

Oncogenic Nras Increases Hematopoietic Stem Cell Proliferation and Self-Renewal Through a Bimodal Effect

Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9 -Specified Gene Expression Signature

MEK Inhibition Modulates the Growth of Nf1 mutant Hematopoietic Cells and Induces Clinical Improvement in a Murine Model of Juvenile Myelomonocytic Leukemia (JMML)

Mechanisms of Relapse Following Targeted Therapy in An NRAS G12V and Mll-AF9 Driven Mouse Model of AML

Heterozygous Germ Line Deletion of a 2Mb Interval in Mice That Models Loss of 7q22 in Human Myeloid Malignancies Results in Defective Hematopoietic Stem Cell Function Reminiscent of Premature Aging

Delineating Critical Effectors of Remission Induction in a Mouse Model of AML

Bcl11a Causes p21 Cip1 Down-Regulation and Transplantable Leukemia in Nf1 -Deficient Mice.

Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition.

A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days.

Bcl11a Causes Leukemia/Lymphoma in Cooperation with Nf1 Inactivation.

RAS and G-CSF Receptor Mutations Are Mutually Exclusive in Leukemogenesis in Severe Congenital Neutropenia.

Oncogenic Ras Requires SHP-2 To Induce Myeloproliferative Disease (MPD).

Multiparameter Flow Cytometric Analysis Reveals Aberrant Phosphorylation of a Network of Effector Molecules in Defined Populations of Kras Mutant Bone Marrow.

Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML).

Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.

Outcomes in CCG-2961, a Children’s Cancer Group Phase III Trial for Untreated Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only